KURA News and Press, Kura Oncology Inc. From 02/27/24

– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008 trial of ziftomenib in combination with additional standards of care, incl...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML – SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical ...

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial result...

2024-02-09 17:44:43 ET More on Kura Oncology Kura Oncology: Ziftomenib's Path To AML Market Widens Kura Oncology: Riding The Menin Hype Wave In AML Therapy Read the full article on Seeking Alpha For further details see: Kura Oncology files to sell 8.7M sh...

SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the Compensati...

2024-01-31 08:30:00 ET Summary Kura Oncology's Progress: Since September, Kura secured a $150 million private placement; stock surged 136%. Clinical Advances: Ziftomenib shows promise in Phase 1 AML trial; particularly effective in NPM1-mutant AML. Financial Health: Strong sho...

2024-01-30 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-30 08:41:38 ET Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dos...

2024-01-30 08:00:49 ET Kura Oncology ( NASDAQ: KURA ) shares jumped as much as 38% premarket on Tuesday after the biopharmaceutical company reported positive preliminary data from a trial evaluating its investigational drug candidate, Ziftomenib, in patients with acute myeloid l...